Search Within

Aaron David Goldberg

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (12)
  3. Research Letter (2)
Groups
  1. Adult Leukemia (30)
  2. Center for Hematologic Malignancies (30)
  3. Department of Medicine (30)
  4. Epidemiology and Biostatistics (30)
  5. Hematologic Malignancies, Division of (30)
  6. Weinberg Fellows (30)

More Groups

People
  1. Martin Tallman (24)
  2. Christopher Famulare (21)
  3. Eytan Stein (19)
  4. Andriy Derkach (18)
  5. Jacob Glass (15)
  6. Mikhail Roshal (14)

More People

Years
  1. 2025 (1)
  2. 2023 (5)
  3. 2022 (4)
  4. 2021 (6)
  5. 2020 (4)
  6. 2019 (4)

More Years

Publications
  1. Blood (15)
  2. Leukemia and Lymphoma (4)
  3. American Journal of Hematology (3)
  4. Blood Advances (3)
  5. Biology of Blood and Marrow Transplantation (1)
  6. Clinical Lymphoma, Myeloma and Leukemia (1)

More Publications

Publishers
  1. American Society of Hematology (18)
  2. Taylor & Francis Group (4)
  3. Elsevier Inc. (3)
  4. John Wiley & Sons, Inc. (3)
  5. Elsevier Ltd (1)
  6. Ferrata Storti Foundation (1)

Results (30)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of pre-transplant measurable residual disease on relapse incidence and progression-free survival in older AML/MDS patients following allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Lin, R. J.; Elko, T. A.; Devlin, S. M.; Perales, M. A.; Papadopoulos, E. B.; Castro-Malaspina, H.; Gyurkocza, B.; Shaffer, B. C.; Tamari, R.; Tallman, M.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy
    Meeting Abstract

    Ball, B. J.; Hsu, M.; Devlin, S. M.; Famulare, C.; Cai, S. F.; Dunbar, A.; Epstein-Peterson, Z. D.; Menghrajani, K.; Glass, J. L.; Taylor, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy
    Meeting Abstract

    Ball, B. J.; Hsu, M.; Devlin, S. M.; Famulare, C.; Cai, S. F.; Dunbar, A.; Epstein-Peterson, Z. D.; Menghrajani, K.; Glass, J. L.; Taylor, J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia
    Journal Article

    Xiao, W.; Goldberg, A. D.; Famulare, C. A.; Devlin, S. M.; Nguyen, N. T.; Sim, S.; Kabel, C. C.; Patel, M. A.; McGovern, E. M.; Patel, A.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • PHF6 mutations are mutually exclusive to TP53 mutations, and define a distinct subgroup of secondary acute myeloid leukemia associated with a primitive stem/progenitor immunophenotype, absent complex karyotype and relatively better outcomes
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Ball, B.; Famulare, C.; Pastore, F.; Tallman, M. S.; Zhang, Y.; Arcila, M. E.; Papaemmanuil, E.; Levine, R. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for persistent measurable residual disease and poor outcomes in acute myeloid leukemia
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Famulare, C.; Delvin, S.; Patel, M.; McGovern, E.; Patel, A.; Schulman, J.; Dunbar, A.; Epstein-Peterson, Z. D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Talati, C.; Desai, P.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Sallman, D. A.; Lancet, J. E.; Roboz, G. J.; Sweet, K. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)
    Meeting Abstract

    Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies
    Meeting Abstract

    Goldberg, A. D.; Horvat, T. Z.; Hsu, M.; Devlin, S. M.; Cuello, B. M.; Daley, R. J.; King, A. C.; Buie, L. W.; Glass, J. L.; Mauro, M. J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Molecular profiling in extramedullary acute myeloid leukemia reveals distinct subgroups defined by mutations in KIT and RUNX1
    Meeting Abstract

    Goldberg, A. D.; Farnoud, N.; Goldberger, C.; Patel, M.; Famulare, C.; Medina, J.; Rampal, R. K.; Levine, R. L.; Berman, E.; Zhang, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save